Annemijn Algra
@annemijn_algra
Stroke Neurologist (almost finished 😎) from 🇳🇱, with a special interest in SAH/ICH, research communication, innovation | Chair of ESOC2024 PR Committee 🧠
ID: 975459717442129920
https://akademienl.social/@annemijn_algra 18-03-2018 19:51:34
551 Tweet
615 Takipçi
1,1K Takip Edilen
The #TASTE #trial supports the use of #Tenecteplase for acute ischemic #stroke <4.5h Though neutral in the intention-to-treat analysis, non-inferiority demonstrated in the per-protocol analysis. Now @ #ESOC2024 👇 European Stroke Org #voiceofstroke
Despite severe disability associated with survival, #SWITCH provides weak evidence for decompressive #craniectomy for severe deep #ICH 🩸🧠 Now at #ESOC2024 & simultaneously in the The Lancet Neurology 👇👏 #ESOC2024 #voiceofstroke @ESOStroke Urs Martin Fischer
The #CONVINCE #trial – now @ #ESOC2024 shows new evidence for #Colchicine in the #prevention of recur. CV events in #stroke. - Prim. analysis: no reduction of recur stroke & CV events - Sec. analyses: reduced events, also in cor. artery subgroup 👇 European Stroke Org #voiceofstroke
The #PESTO #trial found no evidence to support use of arthritis medication #etanercept, sometimes prescribed ‘off-label’ to chronic #stroke patients. An important scientific answer to a question raised by the Stroke Survivors Foundation community Now @ #ESOC2024 👇@ESOStroke #voiceofstroke
Highlighted in the European Stroke Org press portal today — an important study illustrating shocking disparities in #stroke #mortality according to level of #income & #education 👇🏻 eso-stroke.org/wp-content/upl…
🚨STROKE ALERT🚨 if you have not already, be sure to follow European Stroke Org account below ⬇️ Follow live updates from 2nd day of #ESOC2024 🎉
#TRACE3 RCT: TNK (0.25mg/kg) vs BMT for stroke patients between 4.5 - 24h without access to EVT. TNK improved excellent outcome at 90d (RR 1.4 🙌) with no signif. increase in sICH rates ❌️ TNK seemed beneficial across all subgroups #VoiceOfStroke Stroke Trials Stroke: Vascular and Interventional Neurology
The ELAN Trial RCT subanalysis ⏰️ Early vs late start of anticoagulations does not seem to have treatment effect heterogeneity on safety outcomes (sICH, recurrent stroke, mRS>3) ✅️ However, 25%⬆️ risk for mRS>3 in people with PH! Roman Rohner #ESOC2024 #VoiceOfStroke
#RICH2 RCT: Remote ischemic conditioning (RIC) for spontaneous ICH did not show a difference for mRS 0-2 at 90D with comparable safety outcomes (except ⬆️ pain in the ICH group) TREND-IVT study 🇨🇳 #ESOC2024 #VoiceOfStroke